Welcome to our dedicated page for Inmed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
InMed Pharmaceuticals Inc. entered into an amending agreement with Armistice Capital Master Fund to change the terms of certain preferred investment options originally issued on October 26, 2023. These options give Armistice the right to purchase up to 278,761 common shares.
The exercise price for these preferred investment options is being reduced from $16.60 per share to $0.80 per share. The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and there is no assurance any of the options will be exercised.
InMed Pharmaceuticals Inc. entered into an amending agreement with Armistice Capital Master Fund to change the terms of certain preferred investment options originally issued on October 26, 2023. These options give Armistice the right to purchase up to 278,761 common shares.
The exercise price for these preferred investment options is being reduced from $16.60 per share to $0.80 per share. The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and there is no assurance any of the options will be exercised.
InMed Pharmaceuticals Inc. entered into an amending agreement with Armistice Capital Master Fund to change the terms of certain preferred investment options originally issued on October 26, 2023. These options give Armistice the right to purchase up to 278,761 common shares.
The exercise price for these preferred investment options is being reduced from $16.60 per share to $0.80 per share. The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and there is no assurance any of the options will be exercised.
InMed Pharmaceuticals reported third quarter fiscal 2026 results and a business update. The company is winding down BayMedica’s commercial operations, its only revenue-generating business segment, which is classified as discontinued operations and expected to be substantially exited before the fiscal year ending June 30, 2026.
For the three months ended March 31, 2026, InMed recorded a net loss of $3.0 million from total operations, compared with $2.1 million a year earlier, as research and development and general and administrative costs increased. Continuing operations generated no revenue, while discontinued commercial operations produced $0.7 million of revenue that is reported separately.
Cash, cash equivalents and short-term investments were $5.2 million as of March 31, 2026, down from $10.8 million on June 30, 2025. The company highlighted preclinical data for its CB1/CB2-targeting candidate INM-901, showing reduced neuroinflammation in advanced 3D human brain organoid models of Alzheimer’s disease, consistent with earlier in vivo and ex vivo findings.
InMed Pharmaceuticals Inc. has amended existing preferred investment options held by Sabby Volatility Warrant Master Fund and affiliates of H.C. Wainwright & Co. to significantly lower their exercise prices. Sabby’s options for up to 2,151,478 common shares were repriced from $2.436 to $0.80 per share.
Preferred investment options held by three Wainwright affiliates for up to 153,236 common shares, previously exercisable at $82.50, $20.75 and $3.2013 per share, were also repriced to $0.80. All of these options were originally issued in private placements under Section 4(a)(2) and Regulation D. The company later issued a press release describing these amendments.
InMed Pharmaceuticals Inc. filed a prospectus supplement and related prospectus on April 3, 2026 for the sale of its common shares under an existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. These potential sales are made pursuant to a shelf registration statement on Form S-3, which was filed on March 20, 2026 and declared effective on March 30, 2026.
The company also filed a legal opinion from Norton Rose Fulbright Canada LLP as Exhibit 5.1 covering the legality of the common shares issuable under the Sales Agreement and included a related consent as Exhibit 23.1.
InMed Pharmaceuticals Inc. is offering up to $1,213,648 of its common shares in an at-the-market offering through H.C. Wainwright & Co., acting as sales agent or principal.
The prospectus supplement states a 3.0% sales commission to Wainwright, reports a public float of $3,640,946 (based on non-affiliate holdings as of April 1, 2026), and shows 3,314,063 shares outstanding prior to this offering. The document also discloses a Nasdaq minimum bid-price notice and the wind down of BayMedica’s commercial operations with estimated severance and related costs.
InMed Pharmaceuticals received a Nasdaq notice that its common share closing bid price was below the $1.00 minimum for 30 consecutive trading days from February 11 to March 26, 2026, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).
The company has 180 calendar days from March 27, 2026 to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. During this period, its shares will continue trading on the Nasdaq Capital Market under the symbol INM if other listing standards are met.
If InMed cannot meet the requirement within this window, it may qualify for an additional 180-day grace period, potentially using a reverse stock split to lift the share price. Failure to comply after the available periods could lead to delisting, though InMed could appeal to a Nasdaq Hearings Panel.
InMed Pharmaceuticals reported new preclinical results for its INM-901 Alzheimer's disease program, showing positive effects in 3D human brain organoid models of neuroinflammation. In these human tissue-like systems, INM-901 produced dose-dependent reductions in key pro-inflammatory markers such as IL-6 and IL-8.
The anti-inflammatory effects in human organoids were consistent with earlier in vivo Alzheimer's models and ex vivo LPS-induced neuroinflammation studies, supporting translation from animals to human-relevant systems. The company plans a pre-IND meeting with the FDA in Q3 2026 and is targeting an IND submission and Phase 1 trial initiation in 2027, subject to regulatory feedback and completion of IND-enabling work.
$50,000,000 registration: InMed Pharmaceuticals Inc. has filed a shelf prospectus to offer and sell, from time to time, up to $50,000,000 of common shares, preferred shares, warrants, subscription rights and units, in one or more offerings. The prospectus permits sales in any combination and contemplates sales through underwriters, dealers, agents or directly on a continuous or delayed basis.
The filing states the aggregate market value of common shares held by non-affiliates was approximately $2.6 million based on March 18, 2026 closing price of $0.88 and 2,915,074 non-affiliate shares. The audit reports for fiscal years ended June 30, 2025 and June 30, 2024 include explanatory going-concern paragraphs.